GSK Gains Hengrui’s PDE3/4 Inhibitor, Options For 11 Early Assets In Potential $12bn Deal

 
• By Dexter Jie Yan
  
GSK strikes potentially huge deal with China's Hengrui for respiratory, other assets (Shutterstock)

More from Deals

More from Business